OK SB207

Establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to provide guidance on rare disease patient needs, with the Governor appointing the chair by December 1, 2025, and the chair appointing at least 13 members from specified stakeholder groups including patients, caregivers, healthcare providers, researchers, and industry representatives.

Council shall conduct activities including public hearings on rare disease needs, provide testimony on relevant legislation, consult with experts to develop policy recommendations, establish emergency care continuity protocols, identify research gaps, and research best practices to reduce health disparities.

Council must submit annual reports to the President Pro Tempore, Speaker of the House, and Governor describing activities and providing recommendations; initial meeting required by February 1, 2026, with quarterly meetings thereafter conducted under Oklahoma Open Meeting Act.

Council members serve up to three years (four years during initial five-year period for staggered rotation), with chair serving initial three-year term then elected by majority vote every two years; vacancies filled by majority vote in compliance with membership requirements.

Modifies newborn screening requirements to align disorder screening with the Recommended Uniform Screening Panel of the U.S. Department of Health and Human Services; requires State Department of Health to compile and publish annual reports on screened disorders starting November 1, 2026.